Algeria Sets 2027 Deadline for Full Pharmaceutical Traceability: A New Compliance Era for North Africa

The Algerian National Agency for Pharmaceutical Products (ANPP) has officially accelerated its roadmap for drug safety, mandating a comprehensive Serialization and Aggregation system to be fully operational by January 1, 2027. This landmark regulation, aimed at eradicating counterfeit medicines and securing the national supply chain, marks one of the most significant shifts in North African pharmaceutical policy to date.
The Regulation: A Multi-Phase Leap Toward Global Standards The new mandate requires all pharmaceutical products-both imported and locally manufactured-to carry a 2D GS1 DataMatrix code on secondary packaging. This code must contain four critical data elements: the Global Trade Item Number (GTIN), a randomized unique serial number, the batch/lot number, and the expiration date.

However, the Algerian guidelines go beyond simple serialization. To achieve "True Traceability," the ANPP has prioritized Aggregation, requiring manufacturers to establish a digital "Parent-Child" relationship between individual units, bundles, cases, and pallets. By the 2027 deadline, every stakeholder in the supply chain-from the factory floor to the pharmacy-must be capable of verifying product authenticity in real-time.
"Algeria is no longer just following international trends; it is setting a regional benchmark," industry analysts noted. "By requiring full aggregation by 2027, the ANPP is ensuring that the Algerian patient receives only verified, high-quality medication, effectively closing the door on the parallel market."

The Challenge: Integration and Data Integrity For manufacturers, the transition represents a complex technical challenge. Compliance requires more than just high-speed printing; it demands a robust IT infrastructure capable of managing massive volumes of serialization data and reporting directly to the Algerian national repository. With the pilot phases currently underway, the industry is urged to move from the "planning" stage to "implementation" to avoid the last-minute bottlenecks seen in other global markets.

Kevision: Your Strategic Partner for Algeria 2027 As manufacturers look toward the 2027 horizon, Kevision Systems stands ready with a proven, turnkey ecosystem specifically engineered for the North African regulatory landscape.

"Compliance is not a destination; it's a continuous process of securing the supply chain," says a spokesperson for Kevision. "Our KevSecure L4 Enterprise Server is designed to manage the specific SSCC and UID generation requirements of the Algerian mandate, ensuring seamless connectivity from the first pack to the last."
Kevision's modular suite provides a "one-stop" solution for Algeria-bound products:
• PrintSecure & AggreSecure: High-speed L1/L2 hardware for 2D coding and bundle-to-pallet aggregation.
• KevSecure L3/L4: Intelligent software layers that handle serial number provisioning and global reporting.
• Ready for EPCIS: Our systems are pre-configured for the electronic data exchange standards expected by the ANPP.
By combining cutting-edge vision inspection with an end-to-end traceability engine, Kevision enables manufacturers to transform a regulatory hurdle into a competitive advantage. In the race to 2027, Kevision ensures your brand is protected, your data is secure, and your products are trusted.

Kevision Systems
One42
ST-101, Ambli Rd
Ashok Vatika

Media Contact: Info@Kevision.in

Kevision Systems is a global leader in Pharmaceutical Inspection and Track & Trace solutions. With a focus on innovation and reliability, Kevision provides the technology and expertise needed to secure pharmaceutical supply chains across Europe, Asia, and Africa.

This release was published on openPR.